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TRAF2 Is Essential for JNK but Not NF-kB
Activation and Regulates Lymphocyte
Proliferation and Survival
Discrete signaling functions are thought to be initiated
by recruiting different types of intracellular signal trans-
ducers to the TNFR superfamily complexes. Thus far,
two major classes of signal transducers have been iden-
tified. The first is characterized by a conserved death
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domain (Itoh and Nagata, 1993; Tartaglia et al., 1993)³Laboratory Animal Research Center
that enables interaction with TNFR1, Fas (CD95), DR3/§Howard Hughes Medical Institute
Wsl-1/TRAMP/Apo-3, or the TRAIL receptor (Boldin etThe Rockefeller University
al., 1995; Chinnaiyan et al., 1995; Hsu et al., 1995;New York, New York 10021
Stanger et al., 1995; Chinnaiyan et al., 1996; Kitson et
al., 1996; Marsters et al., 1996; Bodmer et al., 1997; Pan
et al., 1997). TNFR1 and Fas (CD95), for example, canSummary
interact with TRADD/FADD(MORT1)/MADD/RIP or FAD-
D(MORT1)/RIP in this manner (Boldin et al., 1995; Chin-TRAF2 is believed to mediate the activation of NF-kB
naiyan et al., 1995; Hsu et al., 1995, 1996a, 1996b;and JNK induced by the tumor necrosis factor receptor
Stanger et al., 1995; Schievella et al., 1997). Clustering(TNFR) superfamily, which elicits pleiotropic responses
of the death domain proteins may lead to the furtherin lymphocytes. We have investigated the physiologi-
recruitment of FLICE (also known as MACH or Mch5)cal roles of TRAF2 in these processes by expressing a
and, subsequently, to cell death (Boldin et al., 1996;lymphocyte-specific dominant negative form of TRAF2,
Fernandes-Alnemri et al., 1996; Muzio et al., 1996; Miller,thereby blocking this protein's effector function. We
1997). A second class of signal transducing moleculesfind that the TNFR superfamily signals require TRAF2
that helps orchestrate the functions of the TNFR super-for activation of JNK but not NF-kB. In addition, we
family members are the TNFR-associated proteinsshow that TRAF2 induces NF-kB±independent anti-
(TRAF), first identified by their association with TNFR2,apoptotic pathways during TNF-induced apoptosis.
CD40, CD30, or LTbR (Hu et al., 1994; Rothe et al., 1994;Inhibition of TRAF2 leads to splenomegaly, lymphade-
Cheng et al., 1995; Moisalos et al., 1995; Regnier et al.,nopathy, and an increased number of B cells. These
1995; Sato et al., 1995; Song and Donner, 1995; Gedrichfindings indicate that TRAF2 is involved in the regula-
et al., 1996; Lee et al., 1996b; Nakano et al., 1996). TRAFtion of lymphocyte function and growth in vivo.
proteins interact with the cytoplasmic tails of the TNFR
superfamily members and are thought to serve as
Introduction adapter proteins to recruit downstream signal transduc-
ers such as NF-kB±inducing kinase (NIK), which is re-
Tumor necrosis factor receptor (TNFR) superfamily sponsible for the activation of NF-kB (Malinin et al.,
members both subserve and govern diverse cellular 1997).
events during development and following infectious in- To date, six members of the TRAF family have been
sult or immunologic challenge (Smith et al., 1994). In found (Hu et al., 1994; Rothe et al., 1994; Cheng et al.,
naive lymphocytes, for example, the TNFRs exert costim- 1995; Moisalos et al., 1995; Regnier et al., 1995; Sato et
ulatory signals for proliferation yet also induce death al., 1995; Song and Donner, 1995; Cao et al., 1996; Na-
signals required for deletion of activated mature T cells kano et al., 1996). None exhibits enzymatic activity, sug-
(Penninger and Mak, 1994; Smith et al., 1994). Such gesting they operate solely as signal adapters. All con-
varied outcomes arise from the selective activation of tain a conserved C-terminal TRAF domain that is used
different signal transduction pathways: the caspase/ for homo- or hetero-oligomerization among the TRAF
interleukin-Ib-converting enzyme cascade, nuclear fac- family and for interactions with the cytoplasmic regions
tor (NF)-kB family of transcription factors, and the mito- of theTNFR superfamily. In addition to theTRAF domain,
gen-activated protein kinases, including both the c-Jun most of the TRAF proteins contain an N-terminal RING
N-terminal protein kinase (JNK) and p38/Mpk2 subsets finger and several zinc finger structures that appear
(Smith et al., 1994; Baker and Reddy, 1996). Caspases critical for their effector functions (Hu et al., 1994; Rothe
are responsible for the proteolytic events leading to et al., 1994; Cheng et al., 1995; Moisalos et al., 1995;
apoptosis (Miller, 1997), whereas NF-kB inhibits cell Regnier et al., 1995; Sato et al., 1995; Song and Donner,
death in many different cell types (Beg and Baltimore, 1995; Cao et al., 1996; Nakano et al., 1996).
1996; Liu et al., 1996; Van Antwerp et al., 1996; Wang The study of TRAF effector functions has been limited
et al., 1996). The JNK and p38/Mpk2 kinases contribute to transient transfection experiments in tumor cell lines.
to AP-1 activation, which can regulate growth signals Nevertheless, a great deal of information is emerging
or induce cytokines (Karin, 1995; Xia et al., 1995). Once about the role of TRAF proteins. TRAF2 is required for
activated coordinately, these convergent signals may NF-kB activation induced by two TNFRs, CD40 and
cause cell proliferation, differentiation, or death (Smith CD30, as well as HVEM/ATAR (Rothe et al., 1995b;
et al., 1994; Baker and Reddy, 1996). Cheng and Baltimore, 1996; Hsu et al., 1996b, 1997;
Lee et al., 1996a; Montgomery et al., 1996). In addition,
TRAF2 mediates JNK activation via TNFR1 (Liu et al.,‖ To whom correspondence should be addressed (e-mail: choi@
rockvax.rockefeller.edu). 1996; Natoli et al., 1997; Reinhard et al., 1997). TRAF5
Immunity
704
is also implicated in NF-kB activation by CD40, LT-bR,
and HVEM/ATAR (Ishida et al., 1996b; Nakano et al.,
1996; Hsu et al., 1997; Reinhard et al., 1997) and in
regulating CD40-mediated CD23 up-regulation in B
cells, a property it shares with TRAF3 (Cheng et al.,
1995; Ishida et al., 1996b). TRAF1 is necessary for the
recruitment of the cellular inhibitor of apoptosis protein
(c-IAP) family to the TNFR2 signaling complex (Rothe
et al., 1995a) and antagonizes T cell apoptosis (Speiser
et al., 1997). Apart from the signaling events initiated by
the TNFR family members, TRAFs may also link other
receptor-mediated signaling pathways. For example,
TRAF6 is a component of interleukin-1 receptor (IL-1R)
signaling complex, in which it induces the activation of
NF-kB following IL-1 binding (Cao et al., 1996).
Despite the elucidation of aspects of TRAF effector
functions by in vitro transfection experiments, almost
nothing is known of the biological role of TRAF proteins
in vivo. The importance of in vivo experiments on the
physiological roles of TRAF proteins is exemplified by
the recent generation of TRAF3-deficient mice; the null Figure 1. Transgenic Mice Overexpressing TRAF2.DN
mutation differed from transfection experiments in that (A) Northern blot analysis of TRAF2 and TRAF2.DN mRNA expres-
it did not produce any significant defects in CD40 signal- sion. Total RNA was isolated from thymocytes (T) and splenocytes
(S) of TRAF2.DN Tg (TG) and its non-Tg (Cont.) littermates anding (Xu et al., 1996). Instead, TRAF3-deficient mice
analyzed by Northern blot analysis using a murine TRAF2 cDNAshowed postnatal lethality and defective T-dependent
probe. Both endogenous TRAF2 (TRAF2) and TRAF2.DN (TRAF2.DN)immune responses, suggesting that TRAF3 is involved
are shown. Level of mRNA expression was quantified by phospho-
in the regulation of other yet to be determined cellular imaging. The amount of total RNA loaded in each lane was similarly
processes during development (Xu et al., 1996). based on ethidium bromide (EtBr)-stained rRNAs (28S rRNA).
Since TRAF2 is thought to occupy a pivotal position (B) Western blot analysis of TRAF2.DN protein expression. Cell ly-
sates from thymocytes (T) and splenocytes (S) of TRAF2.DN Tg (TG)in the signaling pathways initiated by most members of
and its non-Tg (Cont.) littermateswere analyzed using an anti-TRAF2the TNFR superfamily (e.g., TNFR1, TNFR2, CD30,CD40,
polyclonal antibody. Endogenous TRAF2 was undetectable.and LT-bR), we have examined the physiological role of
this multipurpose adapter protein by overexpressing a
dominant negative form of TRAF2 (TRAF2.DN) in vivo.
ResultsTRAF2.DN contains a deletion of the N-terminal RING
and zinc fingers previously shown to operate as a domi-
To examine TRAF2 function specifically in lymphocytes,nant negative inhibitor of NF-kB (Lee et al., 1996a) and
we produced Tg mice that carried TRAF2.DN under theJNK activation (data not shown). A similar N-terminal
control of an H-2K promoter and IgH enhancer (PircherRING finger truncated TRAF2 was also effective as a
et al., 1989a; Pircher et al., 1989b). Levels of TRAF2.DNdominant negative inhibitor of NF-kB and JNK activation
mRNA expression in both the thymus and spleen ofmediated by TNFRs or CD40 (Rothe et al., 1995b; Liu
TRAF2.DN Tg mice exceeded those of endogenouset al., 1996; Natoli et al., 1997; Reinhard et al., 1997),
TRAF2 mRNA by approximately 20-fold when deter-suggesting that most effector functions of TRAF2 re-
mined by Northern blot analysis (Figure 1A). Largequire this region. We chose to inhibit TRAF2 function
amounts of Tg TRAF2.DN protein were also detected inonly in lymphocytes: first, because nearly all the mem-
these organs of TRAF2.DN Tg mice by Western blotbers of the TNFR superfamily play important roles in
analysis (Figure 1B). The level of Tg TRAF2.DN expres-regulating lymphocyte development and function (Pen-
sion was commensurate with that observed for Tgninger and Mak, 1994; Smith et al., 1994), and second,
TRAF1 expressed under the control of the same cis-to avoid the possibility of prenatal or postnatal lethality
acting elements (Speiser et al., 1997). As expected, puri-arising from occult defects associated with global dis-
fied T and B cells expressed similar levels of Tg
ruption as seen for other gene-targeted members of this
TRAF2.DN or TRAF1 (data not shown).
family (e.g., TRAF3) (Xu et al., 1996). Here, we show that
TRAF2.DN Tg mice develop splenomegaly, lymphade-
nopathy, and an abnormal expansion of B cells, sug- TRAF2.DN Expression Inhibits JNK
gesting that TRAF2 contributes to B cell homeostasis. Activation via TNFR and CD40
Inhibition of TRAF2 prevents the activation of JNK but Since TRAF2 has been implicated in the TNFR-mediated
not NF-kB through TNFR or CD40, suggesting that activation of JNK and NF-kB (Rothe et al., 1995b; Liu et
TRAF2 has a specific role in the regulation of JNK path- al., 1996; Natoli et al., 1997; Reinhard et al., 1997), we
way via the TNFR superfamily members. In addition, tested the ex vivo responses of lymphocytes from
TRAF2 is found to activate antiapoptotic signals inde- TRAF2.DN Tg mice to TNF. TNF-induced JNK activation
pendently of NF-kB±activated genes during TNF-medi- was severely impaired in thymocytes from TRAF2.DN
Tg mice but not from TRAF1 Tg or non-Tg littermatesated apoptosis.
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tested the in vitro responses of B cells from TRAF2.DN
Tg mice to CD40L. Resting B cells purified from the
spleens of TRAF2.DN Tg or TRAF1 Tg mice and their
non-Tg littermates were stimulated with soluble murine
CD40L. CD40-mediated JNK activation was impaired
severely in B cells from TRAF2.DN Tg but not from
TRAF1 Tg or non-Tg littermates (Figure 2A). Like thymo-
cytes stimulated with TNF, B cells from TRAF2.DN Tg
mice were unaffected in NF-kB activation following
CD40 engagement (data not shown). TRAF1 overexpres-
sion also failed to perturb CD40-induced NF-kB activa-
tion in B cells (data not shown).
Taken together, these results suggest that TRAF2 but
not TRAF1 is required for JNK activation by TNF or
CD40L. However, in contrast to the results from transient
transfection experiments (Rothe et al., 1995b; Cheng
and Baltimore, 1996; Hsu et al., 1996b), neither TRAF2
nor TRAF1 appears to be necessary for TNF- or CD40-
induced NF-kB activation.
Compromised TCR-Mediated Responses
in TRAF2.DN Tg Mice
To determine whether TRAF2 plays a role in T cell recep-
tor (TCR)-mediated stimulation, we tested the in vitro
responses of T cells from TRAF2.DN Tg mice to anti-
TCR antibody (Ab) treatment. T cells from TRAF2.DN Tg
mice were significantly less responsive to anti-TCR Ab
treatment than T cells from their wild-type controls (Fig-
ure 3A). In contrast, TRAF1 overexpression has little, if
any, influence on TCR-mediated proliferation (Speiser
et al., 1997), suggesting the effect is specific for TRAF2.
In addition to proliferation, TCR engagement can also
mediate cell death. When activated T cells are restimu-
lated with anti-TCR Ab, these cells undergo apoptosis
(activation-induced cell death [AICD]). We have shown
previously that TRAF1 overexpression impairs the AICD
of peripheral T cells (Speiser et al., 1997). To determine
Figure 2. TRAF2 Is Critical for JNK Activation by TNF and CD40L whether TRAF2 exhibits similar properties in primary T
(A) Cell lysates prepared from thymocytes unstimulated (2) or stimu- cells, either independently or as a heterodimer with
lated (1) with TNF (10 ng/ml) for 2.5 min and purified B cells unstimu- TRAF1 (Rothe et al.,1994), we tested whether TRAF2.DN
lated (2) or stimulated (1) with soluble CD40L (1:1000) for 10 min
expression affects AICD. Resting lymph node cells fromwere used to measure JNK activity by immunocomplex kinase assay
TRAF2.DN Tg and non-Tg littermates were primed forwith GST-c-Jun(1-79) as a substrate. Thymocytes (for TNF) or B
apoptosis by concanavalin A (Con A) and IL-2 treatment,cells (for CD40L) were purified from TRAF2.DN transgenic (TG) and
its nontransgenic (cont.) littermates and also from TRAF1 transgenic as described previously (Zheng et al., 1995; Speiser et
(TG) and its nontransgenic (cont.) littermates. JNK activity was in- al., 1997). When restimulated through the TCR, the
creased approximately 4-fold in thymocytes by TNF and approxi- percentage of activated T cells undergoing anti-TCR-
mately 10-fold in B cells by CD40L when determined by phospho-
induced death from TRAF2.DN Tg mice was similarimaging in TRAF1 Tg and control mice. The fold increase in JNK
(60%±80%) to that of activated T cells from negativeactivity in cells from TRAF2.DN mice was less than 1.2. One of three
littermates (Figure 3B). Thus, TRAF2 does not appear torepresentative experiments is shown.
(B) Nuclear extracts (4 mg) prepared from thymocytes unstimulated participate in the signal transduction of TCR-mediated
or increasing amounts of TNF for 15 min were used for gel shift apoptosis, unlike TRAF1 (Speiser et al., 1997).
assays. Affinity-purified NF-kB complexes (0.1 mg) were used as a
positive control (lane c). Arrow, position of the activated NF-kB
complexes. One of four representative experiments is shown. TRAF2.DN Expression Enhances B Cell
Responses to LPS and CD40
Because CD40 signals induce B cell activation and pro-
liferation (Banchereau et al., 1994), we tested the re-(Figure 2A). However, contrary to expectation, TNF-
mediated NF-kB activation was not noticeably affected sponses of B cells from TRAF2.DN Tg mice to anti-
IgM, CD40L, and lipopolysaccharide (LPS) stimulationin thymocytes from TRAF2.DN Tg (Figure 2B) or TRAF1
Tg mice (data not shown). in vitro. In contrast to the attenuated TCR-mediated
proliferative responses, BCR-mediated responses (anti-Besides its reported roles in TNFR1/TNFR2 signaling,
TRAF2 isalso implicated inmediating CD40 signals (e.g., IgM Ab) were not altered significantly in TRAF2.DN Tg
mice (Figure 4A). However, CD40 and LPS responsesNF-kB activation) (Rothe et al., 1995b). Therefore, we
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Figure 4. In Vitro Responses of B Cells to Anti-IgM, LPS, and CD40LFigure 3. In Vitro Proliferation and Apoptosis of Mature T Cells
(A) 3H-thymidine incorporation of purified B cells (5 3 104/well) iso-(A) [3H]Thymidine incorporation of purified T cells (1 3 105/well)
lated from spleens of TRAF2.DN Tg (black bars) and non-Tg (control;isolated from lymph nodes of TRAF2.DN Tg (circle) and non-Tg
indicated as white bars) littermates stimulated by LPS, IgM, CD40L,(control; square) littermates stimulated by plate-bound anti-TCR Ab
and IgM plus CD40L. The data show the mean cpm 6 SEM from(H57-597). The data show the mean counts per minute (cpm) 6
the triplicate samples. The data are from one of four representativestandard error from the mean (SEM) from the triplicate samples.
experiments. Hyperstimulation of TRAF2.DN Tg B cells by IgM (ap-The data are from one of three representative experiments.
proximately 1.5-fold increase) was seen only in two of four experi-(B) The percentages of cell survival in CD41 or CD81 T cells were
ments performed.shown as the mean 6 SEM from the triplicate samples of three
(B) Up-regulation of B7-1, ICAM-1, and CD23 by CD40L. B cellsmice from each group. The data are from one of two representative
from TRAF2.DN Tg (thick line) and non-Tg (dotted line) littermatesexperiments. Specific cell survival (percentage) was determined
were two-color stained with anti-B220 and anti-B7-1 (B7-1), withfrom the percentages of viable (PI2) cells; it equals 100 3 (percent-
anti-B220 and anti-ICAM-1 (ICAM-1), and with anti-B220 and anti-age survival after CD3-crosslinking/percentage survival without
CD23 (CD23) before (Day 0) and after (Day 2) stimulation with CD40L.CD3-crosslinking). T cells were purified from TRAF2.DN Tg (TRAF2.DN)
Only the B2201 cells are shown in the histograms. The data areand non-Tg (control) littermates and activated with ConA plus IL-2.
from one of four representative experiments.Preactivated T cells were then cultured on either uncoated (medium)
or anti-CD3e-coated plate, harvested after 48 hr, and stained with
anti-CD8 Ab-FITC or anti-CD4 Ab-FITC. Viable cells were quantified
that the coinduction of NF-kB-activated antiapoptoticby PI exclusion among cells stained with anti-CD4 or anti-CD8 by
genes with TNF-induced death signals may account forFACS analysis.
the relative resistance of most tumor cell lines to TNF-
induced killing (Beg and Baltimore, 1996; Liu et al., 1996;
Van Antwerp et al., 1996; Wang et al., 1996). This ideawere increased significantly (CD40, 2- to 3-fold; LPS, 2-
to 5-fold) in the TRAF2.DN Tg B cells (Figure 4A). In is supported by the finding of increased TNF-induced
cell death in the absence of NF-kB activation (Beg andaddition to increased proliferation, B cells from TRAF2.DN
Tg mice also up-regulated B7-1, CD23, and ICAM-1 in Baltimore,1996; Liu et al., 1996; Van Antwerp et al.,1996;
Wang et al., 1996) and the observation that TRAF2.DNresponse to CD40L to a higher extent than seen in con-
trol B cells (Figure 4B). enhances the susceptibility of several tumor cells to
TNF-induced apoptosis (Liu et al., 1996).
To determine the role of TRAF2 in the regulation ofTRAF2.DN Expression Enhances TNF-Induced
Cell Death TNF-mediated apoptosis in lymphocytes, TRAF2.DN Tg,
TRAF1 Tg, and wild-type control littermate thymocytesTNF can induce apoptosis in cells of diverse histoge-
netic origin. However, TNF-mediated apoptosis, which were treated with increasing amounts of TNF with or
without cycloheximide (CHX). TNF alone did not induceitself is independent of protein synthesis, requires inhibi-
tion of ongoing protein synthesis in most cell types (Bey- significant cell death in thymocytes from non-Tg or
TRAF1 Tg mice (Figure 5A). However, thymocytes fromaert and Fiers, 1994). Recent experiments suggested
Positive and Negative Roles of TRAF2 in Lymphocytes
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Figure 5. The Enhanced Cytotoxicity of TNF
to Mouse Thymocytes
Thymocytes (2 3 105/well) purified from either
TRAF2.DN Tg (TRAF2.DN) and its non-Tg
(control 1) littermates or from TRAF1 Tg
(TRAF1) and its non-Tg (control 2) littermates,
were incubated for 22 hr with increasing
amounts of (A) TNF alone, (B) TNF plus CHX
(30 mg/ml), or (D) anti-Fas Ab (Jo2) 6 CHX
(30 mg/ml). In (C), TNF-induced cytotoxicity
of activated T cells (1 3 105/well), prepared
from either TRAF2.DN Tg (TRAF2.DN) and its
non-Tg (control 1) littermates or from TRAF1
Tg (TRAF1) and its non-Tg (control 2) lit-
termates, was measured by treating for 22 hr
with increasing amounts of TNF plus CHX (40
ng/ml). In parallel experiments, treatment
with TNF alone for 22 hr did not induce a
significant cell death in activated T cells (data
not shown). Viable cells were then analyzed
by PI uptake. The percentages of cell death
were shown as the mean 6 SEM from the
triplicate samples from each group. Some of
SEMs are not apparent due to their small val-
ues. Specific cell death (percentage) was de-
termined from the percentages of viable (PI2)
cells; it equals 100 3 (12survival after TNF
or Jo2 treatment/survival in media alone in
the presence or absence of CHX). Back-
ground cell death of thymocytes in media 6
CHX alone was approximately 20%±30%.
The data are from one of four (A, B, D) and
three (C) representative experiments.
TRAF2.DN Tg mice showed a moderate increase (ap- thymus and bone marrow contained normal celluarities
(data not shown). The relative number of mononuclearproximately 2-fold; P , 0.001) in sensitivity to TNF-
induced cell death (Figure 5A). Hence, TRAF2 may pro- cells in these organs was increased approximately
3-fold in TRAF2.DN Tg relative to non-Tg littermatesvide antiapoptotic signals during TNF-induced cell
death in thymocytes. Similar results were also obtained (Table 1). Subset analysis of splenocytes and lymph
node cells from TRAF2.DN Tg mice revealed that thewith human TNF, which interacts specifically with murine
TNFR1 but not with TNFR2 (Lewis et al., 1991) (data not increase in mononuclear cells was due to an increase
in CD32B2201 B cells (Figure 6 and Table 2). Peripheralshown).
Our observation that TRAF2 provides antiapoptotic T cells appeared to be unaltered in TRAF2.DN Tg mice
(Figure 6 and Table 2). Since TRAF1 Tg mice did notsignal(s) irrespective of NF-kB activation (Figure 2B)
raises the possibility that NF-kB independent antiapop- show any change in the overall cellularity of either the
spleen or lymph nodes (Speiser et al., 1997), our resultstotic signals are activated by TRAF2 during TNF stimula-
tion. To test this idea, we examined the susceptibility suggest that TRAF2 has a unique role in B cell homeo-
stasis.of thymocytes to TNF-induced apoptosis in the pres-
ence of CHX, thereby preventing any de novo synthesis
of NF-kB-activated antiapoptotic proteins. Even in the Discussion
presence of CHX, thymocytes from TRAF2.DN Tg mice
showed a marked increase (approximately 3-fold; TRAF2 serves as an adapter protein without intrinsic
catalytic activity for a large number of the TNFR super-P , 0.001) in sensitivity to TNF-induced cell death com-
pared with those from TRAF1 Tg or non-Tg littermates family members, including TNFR1, TNFR2, CD30, CD40,
and HVEM/ATAR (Hu et al., 1994, 1997; Rothe et al.,(Figure 5B). Mature T cells from TRAF2.DN Tg mice also
showed a significant increase (3- to 4-fold; P , 0.001) 1994; Cheng et al., 1995; Moisalos et al., 1995; Regnier
et al., 1995; Sato et al., 1995; Song and Donner, 1995;in sensitivity to TNF-induced cell death in the presence
of CHX versus TRAF1 Tg or non-Tg littermates (Figure Gedrich et al., 1996; Lee et al., 1996b; Nakano et al.,
1996). Transient transfection experiments in tumor cell5C). Thus, TRAF2 appears to provide antiapoptotic sig-
nal(s) that are independent of de novo (NF-kB-activated) lines suggested that TRAF2 is required for both NF-kB
activation by TNFR or CD40 (Rothe et al., 1995b) andprotein synthesis.
for JNK activation by TNFR1 (Liu et al., 1996; Natoli et
al., 1997; Reinhard et al., 1997). Here, we have shownSplenomegaly and Lymphadenopathy
in TRAF2.DN Tg Mice that lymphocytes expressing TRAF2 have a dramatic
decrease in JNK activation in response to TNFR or CD40Both the spleen and lymph nodes were hypertrophied
in TRAF2. DN Tg mice (Figure 6 and Table 1), while stimulation. Thus, TRAF2 is likely to be an essential
Immunity
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Figure 6. Splenomegaly and Lymphadenopathy in TRAF2.DN Tg Mice
(A) The hypertrophy of the spleen and lymph nodes in TRAF2.DN Tg mice. Shown are the spleens and lymph nodes (cervical, superficial
inguinal, axillary, lateral axillary) recovered from 12-week-old TRAF2.DN Tg (T) and non-Tg (C) littermates.
(B) Thymus and lymph node profiles of TRAF2.DN Tg mice. FACS analysis of thymocytes (top) and lymph node cells (bottom) from 8-week-
old TRAF2.DN Tg (TRAF2.DN) and non-Tg (control) littermates stained with anti-CD4 and anti-CD8 or with anti-CD3 and anti-B220. Percent
of total cells in each quadrant is indicated. Three mice from each group were analyzed; they are represented in Table 2.
signal transducer for TNF- and CD40-induced JNK acti- TRAF2; thus, a small amount of heterocomplexes of
these two TRAF2 molecules may be recruited to thevation in primary lymphocytes. However, it cannot be
formally excluded that other TRAF proteins (e.g., TRAF5) receptor complex, a recruitment which may be sufficient
for NF-kB but not JNK activation. Alternatively, otherthat are displaced from TNFR or CD40 by TRAF2.DN
may be responsible for JNK activation. Our data from members of TRAF family (or as yet unidentified signaling
molecules) that interact with TNFR or CD40 may beTRAF1 Tg mice argues against this possibility, but one
will need to compare rigorously the signaling by TNFR responsible for the activation of NF-kB through these
receptors; TRAF5, for example, appears to mediate theand CD40 between TRAF2.DN Tg and TRAF2 knock-
out mice to assuage this concern. In contrast to the activation of NF-kB via CD40 (Ishida et al., 1996b).
Stimulation of B cells with CD40L mediates many cel-inhibition of JNK activation, TRAF2.DN failed to inhibit
the NF-kB activation by TNFR or CD40, suggesting that lular events. It promotes the B cell proliferation, survival,
and differentiation, including immunoglobulin classTRAF2 is dispensable for NF-kB activation via both
TNFR and CD40. Failure of TRAF2.DN to inhibit NF-kB switching and germinal center formation, and it induces
up-regulation of cell surface receptors such as B7±1,activation by TNFR or CD40 is in contrast to the results
from transient transfection experiments in tumor cell ICAM-1, and CD23 (Banchereau et al., 1994; Noelle,
1996). In vitro transfection experiments in tumor celllines. This may be because lymphocytes from TRAF2.DN
mice contain both wild-type TRAF2 and truncated lines suggested that four members of the TRAF family
Positive and Negative Roles of TRAF2 in Lymphocytes
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Table 2. Lymphocyte Subsets in TRAF2.DN Transgenic MiceTable 1. Lymphocyte Numbers in Thymus, Spleen, and Lymph
Nodes from TRAF2.DN Transgenic Mice
Percentage of Total Cells
Total No. of Lymphocytes (3 108)
Subsets Control TRAF2.DN
Lymphoid Organ Control TRAF2.DN
Thymus (n 5 3)
CD41CD81 95.3 6 0.8 95.8 6 1.1Thymus (n 5 5) 2.24 6 0.47 1.92 6 0.77
Spleen (n 5 14) 1.61 6 0.22 4.56 6 0.45 CD41CD82 4.0 6 0.7 3.4 6 0.8
CD42CD81 0.4 6 0.1 0.4 6 0.1Lymph nodes (n 5 10)a 0.52 6 0.12 1.76 6 0.29
CD42CD82 0.4 6 0.1 0.3 6 0.1
Data are expressed as means 6 standard deviation. Total thymo- Lymph nodes (n 5 3)
cytes, total spleen cells, and total lymph node cells were isolated CD32B2201 36.0 6 2.8 74.3 6 3.7
and counted. Mice were 7±14 weeks old. Lymphocyte numbers of CD31B2202 62.1 6 2.8 23.8 6 3.6
spleen and lymph nodes in TRAF2.DN mice were significantly higher CD41CD82 41.9 6 2.3 17.0 6 2.0
than those of control littermates; the difference was statistically CD42CD81 21.9 6 1.1 6.8 6 1.0
significant (P , 0.001) by Student's t test. Spleen (n 5 8)
a Lateral axillary, axillary, superficial inguinal, and mesenteric. CD32B2201 63.1 6 4.7 80.1 6 4.7
(9.5 6 1.0)a (33.4 6 3.6)a
CD31B2202 26.9 6 2.0 13.6 6 3.2
(4.4 6 0.4)a (4.7 6 1.7)a
and Jak3 kinase appeared to initiate multiple signal
Data are expressed as means 6 standard deviation. Cells fromtransduction pathways via CD40 in B cells (Hu et al.,
thymi, lymph nodes, and spleens were collected and stained with
1994; Cheng et al., 1995; Ishida et al., 1996a, 1996b; anti-CD4 (FITC) and anti-CD8 (R-PE) or with anti-CD3 (FITC) and
Hanissian and Geha, 1997). TRAF2, TRAF5, and TRAF6 anti-B220 (R-PE) and analyzed on a FACSCalibur. Mice were 7±10
activated NF-kB ( Rotheet al., 1995b; Ishida et al., 1996a, weeks old.
a The total number (3107) of B and T cells in the spleens was calcu-1996b), while TRAF3, TRAF5 and Jak3 appeared to be
lated based on the percentages of cells staining positive with anti-required for CD23 up-regulation in B cells upon CD40
CD3 or anti-B220.stimulation (Cheng et al., 1995; Ishida et al., 1996b;
Hanissian and Geha, 1997). However, a physiological
role of these signal transducers cannot be inferred di-
rectly from transfection experiments in tumor cell lines; of B cells, TCR-induced proliferation of T cells from
TRAF2.DN Tg mice was reduced significantly comparedin contrast to such analyses, TRAF32/2 mice showed
that TRAF3 is not required for CD23 up-regulation via with non-Tg littermates or TRAF1 Tg mice. These results
suggest that TRAF2 serves a positive stimulatory func-CD40 (Xu et al., 1996). In this study, we showed that
TRAF2.DN expression in primary B cells led to impaired tion during TCR-mediated T cell proliferation. In this
regard, it is reminiscent of other TRAF2-interacting TNFRCD40-mediated JNK activation and unexpectedly in-
creased proliferation and up-regulation of B7-1, CD23, family members (e.g., TNF or 4-1BB), which can also
act as costimulatory molecules during TCR-dependentor ICAM-1 expression by CD40 stimulation. How does
TRAF2.DN overexpression lead to enhanced responses mitogenesis (Scheurich et al., 1987; Smith et al., 1994;
Hurtado et al., 1997).of B cells to CD40 signals? Since it is at present unclear
which signal transducers are engaged directly in these This study and previous experiments (Xu et al., 1996)
indicate that functional divergence between TRAF2 andresponses, the following can only be speculated. First,
it is possible that TRAF2 acts as a negative regulator either TRAF1 or TRAF3 exists for the activation of JNK
and NF-kB through either TNFR or CD40 in primary lym-of some of the CD40-mediated B cell functions (e.g.,
proliferation and up-regulation of some of the surface phocytes. In addition, neither TRAF1 nor TRAF3 appears
to be an intrinsic regulator of B cell development andmarkers like CD23), which areactually mediated by other
signal transducers like TRAF5 or Jak. Second, it is also function (Xu et al., 1996; Speiser et al., 1997). Hence,
TRAF1, TRAF2, and TRAF3 may exhibit nonoverlappingpossible that TRAF2.DN itself may signal certain re-
sponses directly, perhaps B cell proliferation orup-regu- and unique in vivo roles during lymphocyte proliferation,
differentiation, and death, as well as during TNFR- orlation of B7, ICAM, and CD23 by CD40. Third, it is possi-
ble that TRAF2.DN may actually displace other TRAF CD40-mediated signaling. Our findings within primary
lymphocytes differ from those of in vitro transfectionproteins (such as TRAF3 or TRAF5) from CD40, which
may act negatively on B cell responses toCD40L. Future experiments in tumor cells, the latter of which indicated
TRAF proteins often shared orexhibited redundant func-experiments with TRAF2.DN expression in the TRAF2
null background may help to reveal which of these mech- tions. Ascertaining the extent of such overlap and dis-
secting the unique roles of each TRAF family memberanisms predominates.
Deregulated B cell responses to physiological stimuli in lymphocyte regulation will require further in vivo ex-
periments.such as CD40L may account for the splenomegaly and
lymphadenopathy observed in TRAF2.DN Tg mice. Un- TRAF2 was implicated previously in NF-kB-dependent
antiapoptotic signals during TNF-mediated apoptosislike the enhanced B cell function observed following
CD40 engagement, proliferation initiated via the BCR of several tumor cell lines (Liu et al., 1996). Consonant
with this, we found that inhibition of TRAF2 heightenedwas not altered noticeably in TRAF2.DN Tg mice. Anti-
gen-induced formation of germinal centers was also TNF-mediated killing of thymocytes, despite failing to
inhibit NF-kB activation (Figures 2 and 5). Moreover,markedly unaffected in TRAF2.DN (data not shown),
suggesting that BCR-mediated function does not re- thymocytes and T cells from TRAF2.DN Tg mice were
much more susceptible to TNF-induced cell death thanquire TRAF2. In contrast to BCR-mediated proliferation
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of the pHSE-39 expression cassette (Pircher et al., 1989a, 1989b).
The pHSE-39 expression cassette contains an H-2K promoter and
an IgH enhancer that drives the transgene expression only in T and
B cells (Pircher et al., 1989a, 1989b; Speiser et al., 1997). Transgene
DNA was isolated by XhoI digestion of the pHSE-TRAF2.DN plasmid
and microinjected into (C57BL/6 3 CBA/J) F2 embryos. Transgenic
founders were identified by Southern analysis of tail DNA, and Tg
lines were established by backcrossing with Balb/C mice. TRAF1
Tg mice were previously described (Speiser et al., 1997).
Northern and Western Blot Analyses
Northern blot analysis using a murine TRAF2 cDNA probe was un-
dertaken as described (Lee et al., 1996b; Speiser et al., 1997). For
Western blot analysis, cell lysates were prepared from thymocytes,
splenocytes, purified T cells and B cells, and analyzed using an anti-
TRAF2 polyclonal antibody (Santa Cruz Biotechnology) as described
previously (Lee et al., 1997).Figure 7. Model Showing Two Independent Antiapoptotic Signaling
Pathways during TNF Stimulation in Lymphocytes
Kinase and NF-kB AssaysTNF-induced NF-kB or JNK activation and apoptosis is thought to
In vitro JNK assays were done as described previously (Reinhardbe initiated by the recruitment of TRADD. The activation of caspases
et al., 1997). Cells (2±5 3 106) were treated with media alone, rMu-by TRADD/FADD leads to apoptosis, while NF-kB activation by
TNFa (R & D Systems), or soluble Mu-CD40L (Foy et al., 1994) andTRADD plus as yet to be determined signal transducers protects
lysed with Triton lysis buffer (20 mM Tris-HCl [pH7.5], 137 mM NaCl,cells from TNF-induced apoptosis. TRAF2 mediates JNK activation
1 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM EDTA, 2 mMand induces NF-kB-independent antiapoptotic signals during TNF
EGTA, 1 mM Na3VO4, 25 mM b-glycerophosphate, 50 mM NaF, 10stimulation.
mM sodium pyrophosphate, 15% [v/v] glycerol, and 1% [v/v] Triton
X-100). Cell lysates were microcentrifuged to remove cell debris,
and the supernatant was transferred to a new tube and incubated
those from non-Tg or TRAF1 Tg mice even in the pres- with 0.3 mg of goat a-JNK1 antibody at 48C for 2 hr (Santa Cruz
ence of CHX, which abolishes de novo protein synthesis. Biotechnology) protein A-Sepharose was added for 1 hr before
washing the beads twice with Triton lysis buffer and twice with JNKTRAF2 may therefore provide previously unidentified
reaction buffer (25 mM HEPES [pH 7.4], 25 mM b-glycerophosphate,antiapoptotic signals during TNF-mediated apoptosis
25 mM MgCl2, 2mM dithiothreitol (DTT), and 0.1 mM Na3VO4). Forthat are independent of NF-kB activation. Onecandidate
the kinase reaction, 1.5±3.0 mg of purified glutathione S-transferase
for the NF-kB independent antiapoptotic signals may be (GST)-c-Jun(1-79) (a gift from Dr. H. Hanafusa, The Rockefeller Uni-
the antiapoptotic proteins, c-IAPs (Rothe et al., 1995a; versity), 0.5 mCi g-[32P]ATP and ATP (20 mM) was incubated with the
Duckett et al., 1996; Liston et al., 1996; Uren et al., 1996), immunoprecipitated JNK in a total volume of 30 mL of JNK reaction
buffer for 20 min at 308C. The reactions were stopped with 2 3which are recruited to the TNFR signaling complex only
loading buffer, boiled for 5 min, and run on a 12% SDS polyacryl-when TRAF2 is also present (Rothe et al., 1995a). The
amide gel electrophoresis (SDS-PAGE).antiapoptotic effect of TRAF2, however, appears to be
To measure NF-kB activation, nuclear extracts prepared fromspecific for TNF-induced cell death, because Fas-medi-
lymphocyte lysates stimulated with media alone, TNF, or CD40L
ated cell death was not affected in TRAF2.DN Tg mice were used for gel-shift assays as outlined previously (Lee et al.,
(Figure 5D). 1996b). An end-labeled, double-stranded, NF-kB±specific oligonu-
cleotide probe containing the two tandemly repeated NF-kB sitesThe results described above indicate that TRAF2 acti-
derived from the human immunodeficiency virus long terminal re-vates signaling pathways separate from NF-kB following
peat (59-ATCAGGGACTTTCCGCTGGGGACTTTCCG-39) was usedTNFR superfamily crosslinking in lymphocytes. Despite
(Pfeffer et al., 1993). Affinity-purified NF-kB complexes were pro-
the lack of NF-kB activation, TRAF2 mediates JNK acti- vided by Dr. H.S. Liou (Cornell University Medical College, New
vation and provides antiapoptotic signals during TNF York).
stimulation (Figure 7). The TRAF2-dependent antiapop-
totic signals do not require de novo macromolecular Flow Cytometric Analysis
Single-cell suspensions prepared from thymus, spleen, lymphsynthesis, and thus appear to play a critical role during
nodes, or activated T and B cells were stained and analyzed bythe early stage of TNF stimulation to prevent cell death,
FACSCalibur (Becton-Dickinson) with Cellquest software (Speiserwhich is itself a rapid process involving activation of
et al., 1997). Fluorescein isothiocyanate (FITC)-conjugated anti-CD4,
preexisting caspases. Both TRAF2-dependent and NF- anti-CD8; and R-PE-conjugated anti-B220, anti-CD8 were pur-
kB-activated antiapoptotic signals probably co-operate chased from GIBCO-BRL. FITC-conjugated anti-CD3, anti-ICAM-1,
to protect cells effectively from accidental death during B220, and biotinylated B7-1, CD23 were purchased from Phar-
mingen.TNF stimulation. Indeed, the signals initiated by the
TNFR superfamily may not only serve to amplify inflam-
In Vitro T Cell Assaysmatory events by inducing various cytokines and immu-
For TCR-mediated proliferation, T cells were isolated from lymphnomodulatory molecules, but they may also render by-
nodes using T cell enrichment columns (Biotex Laboratories; .90%
stander host cells inimical to the effects of cytokine- T cells) and induced to proliferate by titrating them in triplicate
induced cytotoxicity by deliberately eliciting TRAF2. into anti-TCR Ab (H57-597)±coated tissue culture wells containing
mitomycin C±treated splenocytes (5 3 105/well), as described pre-
viously (Speiser et al., 1997). [3H]Thymidine was added 3 days laterExperimental Procedures
for incorporation measured after 8±12 hr (Speiser et al., 1997). Cells
were harvested by a Wallac (Turku, Finland) automated cell har-Generation of TRAF2.DN Transgenic Mice
The pHSE-TRAF2.DN expression vector was generated by cloning vester and read in the Wallac b counter.
For activation-induced T cell death in vitro, lymph node T cellsthe 1D4-epitope tagged murine TRAF2.DN cDNA, TRAF2 (241±501)
(MacKenzie et al., 1984; Lee et al., 1996a) into 59 SalI-BamHI 39 site from TRAF2.DN transgenic and nontransgenic littermates were
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treated with ConA (5 mg/ml) for 48 hr, washed with 10 mg/ml Boldin, M.P., Varfolomeev, E.E.,Pancer, Z., Mett, I.L., Camonis, J.H.,
and Wallach, D. (1995). A novel protein that interacts with the deatha-methylmannoside, and incubated in 50 IU/ml IL-2 to predispose
to apoptosis, as described previously (Zheng et al., 1995). Over 97% domain of Fas/APO1 contains a sequence motif related to the death
domain. J. Biol. Chem. 270, 7795±7798.of these cells were ab TCR1 and were cultured subsequently for 48
hr at 5 3 104/well in anti-CD3e Ab (145-2C11) coated plates in tripli- Boldin, M.P., Goncharov, T.M., Golstev, Y.V., and Wallach, D. (1996).
cate. Viable cellswere then quantified by propidium iodide (PI) exclu- Involvement of MACH, a novel MORT1/FADD-interacting protease
sion using a Becton-Dickinson FACSCalibur with CELLQUEST soft- in Fas/APO-1 and TNF receptor-induced celldeath. Cell 81, 803±815.
ware. Viable cells show low PI fluorescence. Specific cell survival Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D.V.
(percentage) was determined from the percentages of viable (PI2) (1996). TRAF6 is a signal transducer for interleukin-1. Nature 383,
cells and it equals 100 3 (percentage survival after CD3 crosslinking/ 443±446.
percentage survival without CD3 crosslinking). Cells were also
Cheng, G., Cleary, A.M., Ye, Z.-S., Hong, D.I., Lederman, S., andstained with anti-CD4-FITC or anti-CD8-FITC.
Baltimore, D. (1995). Involvement of CRAF1, a relative of TRAF, in
CD40 signaling. Science 267, 1494±1498.In Vitro B Cell Assays
Cheng, G., and Baltimore, D. (1996). TANK, a co-inducer with TRAF2B cells were isolated from spleens by negative panning with mag-
of TNF- and CD40L-mediated NF-kB activation. Genes Dev. 10,netic beads conjugated to anti-mouse Thy1.2 following the manu-
963±973.facturer's protocol (Dynal). Purified B cells (.95%) were seeded at
5 3 104/well and treated with 25 mg/ml of LPS (Sigma), CD40L Chinnaiyan, A.M., O'Rourke, K., Tewari, M., and Dixit, V.M. (1995).
(1/1000 concentration; CD8-gp39 fusion protein derived from insect FADD, a novel death domain-containing protein, interacts with the
cells, a gift from Dr. Randy Noelle; Dartmouth Medical School [Foy death domain of Fas and initiates apoptosis. Cell 81, 505±512.
et al., 1994]), and 5 mg/ml of IgM (Fab)2 fragments (Jackson Immuno- Chinnaiyan, A.M., O'Rouke, K., Yu, G.-L., Lyons, R.H., Garg, M.,
logicals, Massachusetts). 1mCi of 3H-thymidine was added 2 days Duan, D.R., Xing, L., Gentz, R., Ni, J., and Dixit, V.M. (1996). Signal
later for incorporation measured after 18 hr. Cells were harvested transduction by DR3, a death domain-containing receptor related
and read as described for T cells. to TNFR-1 and CD95. Science 274, 990±992.
Duckett, C.S., Nava, V.E., Gedrich, R.W., Clem, R.J., Van Dongen,
Cell-Killing Assay J.L., Gilfillan, M.C., Shiels, H., Hardwick, J.M., and Thompson, C.B.
For thymocyte apoptosis assays, freshly isolated thymocytes (2 3 (1996). A conserved family of cellular genes related to the baculovi-
105 cells/well) were treated with the indicated amounts of rMu-TNFa, rus IAP gene and encoding apoptosis inhibitors. EMBO J. 15, 2685±
rHu-TNFa (R & D Systems), or anti-Mu-Fas monoclonal antibody 2694.
(Jo2; Pharmingen) for 22 hr in the presence or absence of 30 mg/ml
Fernandes-Alnemri, T., Armstrong, R.C., Krebs, J., Srinivasula, S.M.,CHX (Sigma) and the dead cells quantified by flow cytometry after
Wang, L., Bullrich, F., Fritz, L.C., Trapani, J.A., Tomaselli, K.J., Lit-staining with 5 mg/ml propidium iodide, as described previously
wack, G., et al. (1996). In vitro activation of CPP32 and Mch3 by(Ogasawara et al., 1995).
Mch4, a novel human apoptotic cysteine protease containing twoFor TNF-induced killing of activated T cells, lymph node T cells
FADD-like domains. Proc. Natl. Acad. Sci. USA 93, 7464±7469.were treated with ConA (5 mg/ml) plus IL-2 (10 U/ml) for 2 days,
Foy, T.M., Durie, F.H., and Noelle, R.J. (1994). The expansive rolewashed with 10 mg/ml a-methylmannoside to remove ConA, and
of CD40 and its ligand in immunity. Semin. Immunol. 6, 259±266.further incubated in 50 IU/ml IL-2 for an additional 2 days. Activated
T cells (1 3 105 cells/well) were then treated with the indicated Gedrich, R.W., Gilfillan, M.C., Duckett, C.S., Van Dongen, J.L., and
amounts of rMu-TNFa for 22 hr in the presence or absence of 40 Thompson, C.B. (1996). CD30 contains two binding sites with differ-
ng/ml CHX. To reduce background cell death, 50 IU/ml of rIL-2 was ent specificities for members of the tumor necrosis factor receptor-
included in the media at all times. Cell death was then determined associated factor family of signal transducing proteins. J. Biol.
as described above. Chem. 271, 12852±12858.
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